Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro

Oncology Letters

Volumn 7, Issue 1, 2014, Pages 203-208

  Zhou, Yong ^a   Xu, Ying ^a   Wang, Han ^b   Niu, Junjie ^a   Hou, Huaying ^a   Jiang, Yuhua ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b Jining First People's Hospital   (China)

Author keywords

Apoptosis; C6; Gliomas; Histone deacetylase inhibitors; in vitro; Radiosensitization; Valproic acid; X ray

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; VALPROIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; GLIOMA; IMMUNOBLOTTING; IN VITRO STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; RADIOSENSITIZATION; RAT; RNA EXTRACTION; RNA ISOLATION; SURVIVAL RATE; WESTERN BLOTTING; X IRRADIATION;

EID: 84888393803     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1666     Document Type: Article

References (44)

1. Agarwal S, Sane R, Oberoi R, Ohlfest JR and Elmquist WF: Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13: e17, 2011.
2. Berens ME and Giese A: '... those left behind.' Biology and oncology of invasive glioma cells. Neoplasia 1: 208-219, 1999.
3. Régnard P, Bräuer-Krisch E, Troprès I, Keyriläinen J, Bravin A and Le Duc G: Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy. Eur J Radiol 68: S151-S155, 2008.
4. Spence AM, Rasey JS, Dwyer-Hansen L, et al: Toxicity, biodistribution and radioprotective capacity of L-homocysteine thiolactone in CNS tissues and tumors in rodents: comparison with prior results with phosphorothioates. Radiother Oncol 35: 216-226, 1995.
5. Bernstein M, Cabantog AM, Glen J, Stiver S and Mikulis D: Tirilazad does not protect rat brain from brachytherapy-induced injury. Surg Neurol 45: 482-489, 1996.
6. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
7. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002.
8. Hess-Stumpp H: Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84: 109-121, 2005.
9. Camphausen K, Scott T, Sproull M and Tofilon PJ: Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10 (18 Pt 1): 6066-6071, 2004.
10. Sheehan J, Ionescu A, Pouratian N, et al: Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation: laboratory investigation. J Neurosurg 108: 972-978, 2008.
11. Marks PA and Xu WS: Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608, 2009.
12. Shabason JE, Tofilon PJ and Camphausen K: Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 15: 2735-2744, 2011.
13. Peterson GM and Naunton M: Valproate: a simple chemical with so much to offer. J Clin Pharm Ther 30: 417-421, 2005.
14. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA and Klein PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741, 2001.
15. Göttlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
16. Marks PA, Miller T and Richon VM: Histone deacetylases. Curr Opin Pharmacol 3: 344-351, 2003.
17. Chen Y, Tsai YH and Tseng SH: Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. J Neurooncol 109: 23-33, 2012.
18. Camphausen K and Tofilon PJ: Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 25: 4051-4056, 2007.
19. Camphausen K, Cerna D, Scott T, et al: Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114: 380-386, 2005.
20. Camphausen K, Burgan W, Cerra M, et al: Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64: 316-321, 2004.
21. Kim JH, Shin JH and Kim IH: Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 59: 1174-1180, 2004.
22. Zhang Y, Jung M, Dritschilo A and Jung M: Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161: 667-674, 2004.
23. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW and Hallahan DE: Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 66: 11298-11304, 2006.
24. Folkvord S, Ree AH, Furre T, Halvorsen T and Flatmark K: Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys 74: 546-552, 2009.
25. Chen X, Wong P, Radany E and Wong JY: HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24: 689-699, 2009.
26. Munshi A, Kurland JF, Nishikawa T, et al: Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11: 4912-4922, 2005.
27. Baschnagel A, Russo A, Burgan WE, et al: Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 8: 1589-1595, 2009.
28. López-Soto A, Folgueras AR, Seto E and Gonzalez S: HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 28: 2370-2382, 2009.
29. Benitez JA, Arregui L, Cabrera G and Segovia J: Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression. Neuroscience 156: 911-920, 2008.
30. Yu H: Typical cell signaling response to ionizing radiation: DNA damage and extranuclear damage. Chin J Cancer Res 24: 83-89, 2012.
31. Santivasi WL and Xia F: The role and clinical significance of DNA damage response and repair pathways in primary brain tumors. Cell Biosci 3: 10, 2013.
32. Groselj B, Sharma NL, Hamdy FC, Kerr M and Kiltie AE: Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 108: 748-754, 2013.
33. Cui YH, Liang HJ, Zhang QQ, et al: Radiosensitivity enhancement by arsenic trioxide in conjunction with hyperthermia in the EC-1 esophageal carcinoma cell line. Asian Pac J Cancer Prev 13: 1693-1697, 2012.
34. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868, 1998.
35. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM and Meyn RE: Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5: 1967-1974, 2006.
36. Zhang Y, Adachi M, Zhao X, Kawamura R and Imai K: Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyri-din-3-yl-methoxycarbonyl)amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer 110: 301-308, 2004.
37. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ: Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139: 1281-1292, 1997.
38. Putcha GV, Deshmukh M and Johnson EM Jr: BAX translocation is a critical event in neuronal apoptosis: regulation by neuroprotectants, BCL-2, and caspases. J Neurosci 19: 7476-7485, 1999.
39. Thomas A, El Rouby S, Reed JC, et al: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 12: 1055-1062, 1996.
40. Yanase N, Takada E, Yoshihama I, Ikegami H and Mizuguchi J: Participation of Bax-alpha in IFN-alpha-mediated apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res 18: 855-861, 1998.
41. Lin HI, Lee YJ, Chen BF, et al: Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells. Cancer Lett 230: 248-259, 2005.
42. Kim DS, Jeon SE, Jeong YM, Kim SY, Kwon SB and Park KC: Hydrogen peroxide is a mediator of indole-3-acetic acid/horseradish peroxidase-induced apoptosis. FEBS Lett 580: 1439-1446, 2006.
43. Zuliani T, Obriot H, Tual M, et al: Variable Bax antigenicity is linked to keratinocyte position within epidermal strata and UV-induced apoptosis. Exp Dermatol 17: 125-132, 2008.
44. Park SK, Kang H and Kwon CH: Caspase-dependent cell death mediates potent cytotoxicity of sulfide derivatives of 9-anilinoacridine. Anticancer Drugs 19: 381-389, 2008.